Jaguar Gene Therapy
Shannon Lindberg has over 20 years of experience in the pharmaceutical industry. Their most recent role is as the Vice President of External Manufacturing at Jaguar Gene Therapy, a position they have held since February 2020. Prior to that, they worked at AveXis, Inc. for four years as the Site Quality Director. Before AveXis, Inc., Shannon was the Contract Manufacturing Director at Pfizer from 2014 to 2016. Shannon spent a significant portion of their career at Hospira, where they held various roles including Contract Manufacturing Manager, Biological Quality Manager, New Products Manager, Contract Manufacturing Analyst, and Production Supervisor. Shannon started their career at Abbott as an Aseptic Corridor monitor.
Shannon Lindberg pursued their education at Emporia State University from 1998 to 2000, earning a Master of Science (M.S.) degree in Molecular Biology.
Jaguar Gene Therapy
Jaguar Gene Therapy is accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases. Led by the former AveXis leadership team and backed by Deerfield Management, a healthcare-specific investment firm, Jaguar brings streamlined R&D, manufacturing and clinical operations to accelerate development and potential approval of therapies for severe genetic diseases.